Story · Medicine & Biotech · Mind & Brain

SGLT2 Inhibitors Versus Metformin as First-Line Therapy for Cardiorenal Outcomes: A Target Trial Emulation Among New Users With Type 2 Diabetes

1 outlet · first reported by Mayo Clinic Proceedings on

To compare cardiorenal and mortality outcomes associated with initiation of sodium-glucose cotransporter-2 (SGLT2) inhibitors versus metformin as first-line glucose-lowering therapy among new users with type 2 diabetes. (Mayo Clinic Proceedings)

Coverage, in order

  1. Mayo Clinic Proceedings indie study observational
    SGLT2 Inhibitors Versus Metformin as First-Line Therapy for Cardiorenal Outcomes: A Target Trial Emulation Among New Users With Type 2 Diabetes

    To compare cardiorenal and mortality outcomes associated with initiation of sodium-glucose cotransporter-2 (SGLT2) inhibitors versus metformin as first-line glucose-lowering therapy among new users with type 2 diabetes.

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.